Omada Health, Inc. (OMDA) Stock Analysis and Metrics

Omada Health

NASDAQ: OMDA

$20.52 ▼ -0.68 (-3.21%)

At close: Jul 24, 2026 · 3:59 PM UTC

Financial Ratios

Market Cap1.25 Bn

P/E-198.28

P/S4.41

Div. Yield0.00

Revenue Growth (1y) (Qtr)42.00

Add ratio to table…

About

Omada Health, Inc. delivers virtual care programs designed to improve health outcomes for individuals with chronic conditions such as prediabetes, diabetes, hypertension, and musculoskeletal disorders between doctor visits.

The company generates revenue by selling its health programs to employers, health plans, pharmacy benefit managers, and health systems that cover the cost of care for their members, patients, or employees, with pricing based on member engagement and clinical outcomes.

The company operates through the following segments: Prevention & Weight Health, Diabetes, Hypertension, Musculoskeletal (MSK), and GLP-1 Care Tracks.

• The Prevention & Weight Health program focuses on prediabetes and weight management through personalized learning paths, health coaching, and connected devices such as scales to support healthy behaviors.

• The Diabetes program supports members with type 1 or type 2 diabetes in achieving stable blood glucose levels through health coaching, specialist support, connected glucose monitors, and personalized feedback.

• The Hypertension program helps members reduce and maintain healthy blood pressure via health coaching, hypertension specialists, connected blood pressure monitors, and lifestyle modification support.

• The Musculoskeletal program provides virtual physical therapy through licensed physical therapists, exercise guidance, and computer vision technology to improve mobility and reduce pain.

• The GLP-1 Care Tracks are embedded within cardiometabolic programs to support members using glucagon-like peptide-1 medications with behavioral coaching, lifestyle resources, and weight management strategies before, during, and after therapy.

Omada Health, Inc. holds a differentiated position in the virtual chronic care market through its Compassionate Intelligence model, which integrates human-led Care Teams with technology personalization, and has earned clinical validations including CDC recognition, NCQA accreditation, and URAC certification for its programs.

The company serves employers such as Costco, Honda, and Intermountain Health; health plans including Cigna Healthcare; pharmacy benefit managers like Express Scripts by Evernorth; and health systems such as Louisiana Office of Group Benefits and the State of Alaska.

Investment Thesis

▲ Bull case

Omada is building a structural margin tailwind from its AI investments that is significantly underappreciated by the market, with the company citing AI-assisted development accelerating product velocity and routine manual processes being converted into automated workflows that create capacity without adding cost, which directly contributes to operating leverage; this is not a temporary efficiency gain but a foundational shift enabling the business to scale prescribing capabilities, multi-condition expansion, and new channel partnerships like Optum Rx and Lilly Employer Connect without proportional cost increases, positioning Omada to exceed its long-term 70% gross margin target as AI maturity compounds over 2027 and beyond, a trajectory the market is pricing as incremental rather than transformative. The company's multi-condition member base is undergoing a durable structural shift where a higher proportion of members are in year 2+ of tenure, which reduces blended revenue per member in the short term but meaningfully increases gross profit per member due to lower front-loaded costs in later years, creating a self-reinforcing profitability model where longer-tenured members become the highest-margin cohort; this dynamic is already evident in Q1's positive adjusted EBITDA despite being the historically most cost-intensive quarter, and the market is misinterpreting the near-term revenue per member moderation as a weakness rather than recognizing it as the leading indicator of a superior unit economics profile that will drive margin expansion as the cohort matures. Omada's GLP-1 strategy is uniquely positioned to capture employer demand across the entire coverage spectrum—from those already covering medications via PBMs to those seeking defined contribution alternatives—by acting as the clinical backbone in diverse benefit designs, a flexibility that is generating broad-based pipeline growth and enabling the company to meet employers where they are without requiring them to adopt a single solution, which is driving multi-condition penetration as GLP-1s serve as a gateway to broader cardiometabolic care, yet the market remains focused narrowly on medication coverage debates rather than recognizing Omada's role as the indispensable care coordination layer that maximizes the value of GLP-1 investments and sustains outcomes post-discontinuation.

Omada is building a structural margin tailwind from its AI investments that is significantly underappreciated by the market, with the company citing AI-assisted development accelerating product velocity and routine manual processes being converted into automated workflows that create capacity without adding cost, which directly contributes to operating leverage; this is not a temporary efficiency gain but a foundational shift enabling the business to scale prescribing capabilities, multi-condition expansion, and new channel partnerships like Optum Rx and Lilly Employer Connect without proportional cost increases, positioning Omada to exceed its long-term 70% gross margin target as AI maturity compounds over 2027 and beyond, a trajectory the market is pricing as incremental rather than transformative. The company's multi-condition member base is undergoing a durable structural shift where a higher proportion of members are in year 2+ of tenure, which reduces blended revenue per member in the short term but meaningfully increases gross profit per member due to lower front-loaded costs in later years, creating a self-reinforcing profitability model where longer-tenured members become the highest-margin cohort; this dynamic is already evident in Q1's positive adjusted EBITDA despite being the historically most cost-intensive quarter, and the market is misinterpreting the near-term revenue per member moderation as a weakness rather than recognizing it as the leading indicator of a superior unit economics profile that will drive margin expansion as the cohort matures. Omada's GLP-1 strategy is uniquely positioned to capture employer demand across the entire coverage spectrum—from those already covering medications via PBMs to those seeking defined contribution alternatives—by acting as the clinical backbone in diverse benefit designs, a flexibility that is generating broad-based pipeline growth and enabling the company to meet employers where they are without requiring them to adopt a single solution, which is driving multi-condition penetration as GLP-1s serve as a gateway to broader cardiometabolic care, yet the market remains focused narrowly on medication coverage debates rather than recognizing Omada's role as the indispensable care coordination layer that maximizes the value of GLP-1 investments and sustains outcomes post-discontinuation.

▼ Bear case

Omada's reliance on channel partnerships with PBMs and health plans introduces significant execution risk, as the company acknowledged that serving newly covered populations through these channels can take multiple sales cycles to build into, and while it has relationships with the three largest PBMs, the actual revenue contribution from newer agreements like Optum Rx and Lilly Employer Connect is not expected to materialize meaningfully until 2027, creating a disconnect between current enthusiasm for partnership announcements and the delayed financial impact, which could lead to disappointment if the market expects near-term revenue conversion from these initiatives. The company faces mounting pressure from macroeconomic and geopolitical volatility, exemplified by its acknowledgment that the conflict in Iran has already increased device-related shipping costs and is estimated to impact full-year results by roughly $1 million, a non-trivial headwind for a business still scaling toward profitability, and while Omada is evaluating pre-purchasing devices as a hedge, this highlights vulnerability to supply chain disruptions that could erode gross margin gains from operational efficiency, particularly as the company seeks to expand its device-dependent programs like glucose monitoring and blood pressure cuffs across its expanding member base. Despite progress in retention and multi-condition penetration, Omada's core business model remains dependent on employer benefit cycles and enrollment timing, with the CFO noting that Q1 is historically the most cost-intensive quarter due to higher enrollment volume and related care team and device costs, and while the company delivered positive adjusted EBITDA in Q1 this year, this outcome may not be repeatable if enrollment effectiveness slows or if new member acquisition costs rise, suggesting that the current profitability inflection point could be fragile and contingent on sustaining historically strong enrollment marketing efficiency rather than representing a structural, durable shift in the business model.

Omada's reliance on channel partnerships with PBMs and health plans introduces significant execution risk, as the company acknowledged that serving newly covered populations through these channels can take multiple sales cycles to build into, and while it has relationships with the three largest PBMs, the actual revenue contribution from newer agreements like Optum Rx and Lilly Employer Connect is not expected to materialize meaningfully until 2027, creating a disconnect between current enthusiasm for partnership announcements and the delayed financial impact, which could lead to disappointment if the market expects near-term revenue conversion from these initiatives. The company faces mounting pressure from macroeconomic and geopolitical volatility, exemplified by its acknowledgment that the conflict in Iran has already increased device-related shipping costs and is estimated to impact full-year results by roughly $1 million, a non-trivial headwind for a business still scaling toward profitability, and while Omada is evaluating pre-purchasing devices as a hedge, this highlights vulnerability to supply chain disruptions that could erode gross margin gains from operational efficiency, particularly as the company seeks to expand its device-dependent programs like glucose monitoring and blood pressure cuffs across its expanding member base. Despite progress in retention and multi-condition penetration, Omada's core business model remains dependent on employer benefit cycles and enrollment timing, with the CFO noting that Q1 is historically the most cost-intensive quarter due to higher enrollment volume and related care team and device costs, and while the company delivered positive adjusted EBITDA in Q1 this year, this outcome may not be repeatable if enrollment effectiveness slows or if new member acquisition costs rise, suggesting that the current profitability inflection point could be fragile and contingent on sustaining historically strong enrollment marketing efficiency rather than representing a structural, durable shift in the business model.

Segments Breakdown of Revenue (2025)

Peer Comparison

Companies in the Health Information Services

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	VEEV	Veeva Systems Inc	29.34 Bn	31.16	8.84	-
2	BTSG	BrightSpring Health Services, Inc.	13.49 Bn	46.18	0.99	2.50 Bn
3	HQY	Healthequity, Inc.	7.96 Bn	34.51	5.95	0.94 Bn
4	TXG	10x Genomics, Inc.	6.17 Bn	-272.14	9.65	-
5	HNGE	Hinge Health, Inc.	6.02 Bn	-11.77	9.31	-
6	MMED	MiniMed Group, Inc.	4.19 Bn	-8.88	1.38	-
7	WAY	Waystar Holding Corp.	4.14 Bn	32.80	3.58	1.47 Bn
8	DOCS	Doximity, Inc.	3.82 Bn	19.51	5.93	-

Research Tools

Developers

About

Investment Thesis

Product and Service Breakdown of Revenue (2025)

Segments Breakdown of Revenue (2025)

Peer Comparison

Research Tools

Developers

About

Investment Thesis

Product and Service Breakdown of Revenue (2025)

Segments Breakdown of Revenue (2025)

Peer Comparison

Create an account

Sign In

Reset Password